How Wearables Walk the Line Between Wellness Tool and Medical Device
As wearables track hormones, blood pressure, and heart rhythm, regulators are drawing new lines health-tech users need to understand.
Summary
Wearables have evolved from step counters into sophisticated health platforms monitoring cardiac rhythms, blood pressure, hormones, and more. This article examines the regulatory tightrope companies walk between being classified as consumer wellness devices versus FDA-regulated medical devices. The distinction matters enormously: a medical device classification requires premarket authorization, clinical validation, and ongoing oversight. The WHOOP 'Blood Pressure Insights' case is a central example — the FDA issued a 2025 warning letter saying the feature crossed into device territory, then clarified guidance in early 2026. For health-conscious consumers, understanding these distinctions helps evaluate which wearable outputs are clinically validated versus general wellness estimates, and how much weight to place on device-generated health insights.
Detailed Summary
Wearables are no longer passive fitness trackers. Today's devices continuously monitor physiological signals — heart rhythm, blood pressure, hormone levels, sleep stages, and more — feeding AI-driven insights into what companies envision as a personal health operating system. That ambition is colliding head-on with a regulatory framework not designed for this convergence of consumer technology and clinical medicine.
The legal boundary hinges on intended use. Under the Federal Food, Drug, and Cosmetic Act, a product becomes a regulated medical device when it is intended to diagnose, treat, or prevent disease. The 2016 21st Century Cures Act created a 'general wellness' carveout for low-risk lifestyle products, and wearable companies have leaned heavily on this exemption as features grow more clinically sophisticated.
The WHOOP case crystallized the stakes. In 2025, the FDA issued a warning letter concluding that WHOOP's Blood Pressure Insights feature constituted an uncleared medical device due to its cardiovascular disease-related claims. WHOOP publicly contested the ruling, prompting the FDA to issue updated 2026 guidance clarifying that wearables can measure physiological parameters — including blood pressure — within the wellness category, as long as outputs are framed as general insights rather than clinical diagnoses.
For longevity-focused consumers, the implications are practical. Features that carry FDA clearance — like Apple Watch's ECG, cleared via De Novo pathway in 2018 — have undergone clinical validation. Features marketed as 'insights' without clearance may lack that evidentiary foundation. Wearables are also entering longevity research directly, with WHOOP participating in the federally backed ARPA-H Prospr program targeting age-related disease biomarkers.
The key caveat is that regulatory status is not a perfect proxy for accuracy or clinical usefulness. Cleared devices still vary in real-world performance. Consumers should understand whether a wearable feature is FDA-cleared, wellness-categorized, or somewhere in regulatory limbo before acting on its outputs in health decision-making.
Key Findings
- FDA's 2025 WHOOP warning letter established that blood pressure estimation with disease-related claims requires premarket device authorization.
- FDA's 2026 updated guidance allows wearables to track physiological parameters within wellness category if outputs avoid clinical diagnostic claims.
- Apple Watch ECG remains the benchmark: a consumer wearable feature that achieved FDA De Novo clearance through clinical validation.
- Wearables like WHOOP are entering federally funded longevity research via ARPA-H Prospr, targeting biomarkers of age-related disease.
- Continuous hormone monitoring wearables and neurotechnology headbands are expanding wearable domains with unclear regulatory status.
Methodology
This is a legal and regulatory analysis article from Longevity.Technology, authored by a partner at ArentFox Schiff law firm. It draws on FDA guidance documents, warning letters, and statutory law rather than clinical trial data. The sourcing is credible for regulatory context but reflects a legal practitioner's perspective rather than independent scientific review.
Study Limitations
The article is truncated and does not include the full discussion of consumer protection intersections. It reflects the regulatory landscape as of early 2026 and may not capture subsequent FDA guidance updates. Legal interpretation of device classification can shift rapidly as enforcement priorities evolve.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.